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Abstract
Background: F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is
increasingly used for the initial staging and restaging of lung cancer. Incidental gastrointestinal findings are often
observed on 18F-FDG PET/CT. The objective of this study was to assess incidental 18F-FDG uptake by the
gastrointestinal tract (GIT) in patients with lung cancer.
Methods: Two hundred thirty consecutive 18F-FDG PET/CT examinations performed for lung cancer over a 3-year
period were retrospectively reviewed for the presence of incidental FDG uptake in the GIT. The charts of patients
with positive FDG uptake were then reviewed and analysed to determine the GIT uptake sites, the standardized
uptake value (SUV) max and the final clinical diagnosis.
Results: Fifty-two patients (52/230, 23 %) demonstrated incidental FDG uptake in the GIT. Thirty-three patients (63.5 %)
had diffuse uptake (oesophagus, n= 2, colon, n = 31) and 19 patients (36.5 %) had focal uptake (oesophagus, n = 1, small
bowel, n = 1, ascending colon, n = 5, descending colon, n = 4, sigmoid, n= 4, rectum, n = 3, and anal margin, n = 1).
Twelve of the 52 patients with GIT uptake were further investigated, revealing, a diagnosis of malignancy in 4 patients
with focal FDG uptake. No significant differences in mean SUVmax were observed between patients with malignant and
benign GIT diseases.
Conclusion: This study demonstrates a high incidence of FDG uptake in the GIT associated with lung cancer. Focal GIT
uptake was frequently associated with malignant disease. These results suggest that further GIT investigations should be
performed in patients with focal GIT uptake.
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Background
Lung cancer is the most common cause of cancer-related
deaths worldwide. The best chance for cure in these pa-
tients is complete surgical resection. However, the overall
5-year survival rate does not exceed 20 % [1]. In view of the
high incidence of metastatic disease in lung cancer, accurate
tumour staging is an essential and critical step for the
choice of optimal treatment strategies. TNM stage is the
most important prognostic factor to guide treatment deci-
sions [2, 3]. Staging typically includes imaging techniques
such as computed tomography (CT), magnetic resonance
imaging (MRI), and bone scintigraphy. Positron emission
tomography, using the glucose analogue 18F-fluorodeoxy-
glucose (18F-FDG-PET/CT), is increasingly used for initial
staging, restaging and monitoring of response to treatment
of lung cancer [4–10]. It has been demonstrated to be an
effective tool, providing more precise and reliable assess-
ment than conventional methods and it has become the
standard of care for these purposes [11].
As a result of the increased availability of 18F-FDG
PET/CT for patients with malignancy, unexpected 18F-
FDG uptake has been identified in a variety of sites,
including the gastrointestinal tract (GIT) [12, 14]. Inci-
dental gastrointestinal uptake is found in about 3 % of
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patients undergoing evaluation for non-gastrointestinal
diseases [15]. The mechanism of increased 18F-FDG up-
take in the GIT is unclear, but may be related to physio-
logical, inflammatory, benign or malignant processes. Two
different patterns of GIT 18F-FDG uptake have been de-
fined on PET/CT examination: focal and diffuse [16].
While diffuse 18F-FDG uptake is generally correlated with
a physiological uptake, focal 18F-FDG uptake can be asso-
ciated with a detectable disease such as primary tumour,
sites of unusual metastatic spread or premalignant lesions.
Previous reports have evaluated the incidence and clinical
significance of incidental gastrointestinal 18F-FDG uptake
and concluded that this finding deserves further appropri-
ate investigation [12, 23].
The objectives of this retrospective study were to
evaluate incidental 18F-FDG uptake in the GIT observed
in a patient population assessed by PET/CT for staging
or restaging of lung cancer and to assess the clinical sig-
nificance of these unexpected findings.
Methods
Patients
We performed a retrospective review of 230 consecutive
patients who underwent 18F-FDG PET/CT for lung can-
cer staging or restaging between January 2011 and Janu-
ary 2014 in the Reims Regional Cancer Centre (Jean
Godinot Institute, IJG). When several 18F-FDG PET/CT
examinations were performed in the same patient, only
the first 18F-FDG PET/CT was analysed. This study was
approved by the Reims University Hospital Institutional
Review Board (IRB).
Patients with incidental FDG uptake in the gastro-
intestinal tract (GIT) were identified by reviewing PET/
CT reports. One person (JVB) assessed all PET/CT re-
ports. Incidental GIT FDG uptake was described accord-
ing to two patterns, focal and diffuse uptake compared
to background activity assessed by the nuclear medicine
physicians. All cases of incidental FDG uptake in the
GIT were analysed. The following data were extracted
for all patients (n = 230): demographic data, indications
for 18F-FDG PET/CT, histology and clinical stage of lung
cancer, and extrathoracic FDG-uptake with organ
localization. In patients with GIT FDG uptake, data con-
cerning 18F-FDG PET/CT, GIT investigations and final
diagnosis of incidental GIT findings were also extracted.
18F-FDG PET/CT protocol
PET examinations were performed with a Gemini-Dual
(Philips®) PET/CT camera, according to a standard
protocol for cancer imaging. Briefly, PET/CT acquisition
was performed as follows: 3 min in each bed position
covering the body between the pelvis and the base of the
skull one hour after peripheral intravenous injection of
5 MBq/kg of 18F-FDG in patients fasted for at least 6 h
before the examination, and low-dose unenhanced CT
(standard acquisition parameters: 100 mAs, 120 kV tube
voltage, 1.5 pitch, 6.5 mm slice thickness). A nuclear
medicine physician reviewed all 18F-FDG PET/CT exam-
inations demonstrating GIT uptake (52/230 PET/CT
were assessed by one nuclear medicine physician (DP))
to determine the maximum standardized uptake value
(SUVmax) of all patients. SUVpeak (mean of SUV in a
spherical volume of interest of approximately 1 mL in a
position that provided the maximal average in the area
of uptake) was also obtained for patients with focal FDG
uptake. Two additional measurements of the metabolic
volume using different definitions of volumes of interest
with varying isocontours (3D isocontour at 50 % and
41 % of the maximum pixel value) were also calculated.
GIT
The GIT was divided into the oesophagus, stomach, small
bowel, colon, rectum and anal margin. In our study, the
final diagnoses were classified as i) “malignant disease con-
firmed” when the malignant disease was confirmed by
histopathology, ii) “high probability of malignant disease”
when the malignant disease was not confirmed by endos-
copy and histopathology but was highly probable based on
follow-up data including clinical findings, CT, new FDG-
PET/CT and/or endoscopy, iii) “benign disease confirmed”
when endoscopy was normal, and iv) “high probability of
benign disease” when endoscopy was not performed but no
sign of malignant GIT disease was detected on follow-up
data including clinical findings, CT, new FDG-PET/CT and/
or endoscopy.
Statistical analysis
Quantitative variables are expressed as mean ± standard
deviation (SD) and qualitative variables are expressed as
number and percentage. Student test and Chi-square
test were performed to compare patient characteristics
between positive or negative GIT FDG uptake. Mann–
Whitney test was performed to compare SUV between
the 4 groups of diagnosis. A p value < 0.05 was consid-
ered statistically significant. All analyses were performed
using Epi Info version 7.0.
Results
Patient characteristics
18F-FDG PET/CT was performed in 230 patients with lung
cancer between January 2011 and January 2014. Incidental
FDG uptake in the GIT was reported in 52 of these pa-
tients, representing a prevalence of 22.6 % (Fig. 1).
Patient characteristics are described in Table 1. The
mean age was 66 ± 9 years in the PET/CT GIT posi-
tive group and 62 ± 10 years in the PET/CT GIT
negative group (p < 0.05). Both groups comprised a
majority of men, and the primary lung cancer
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histology was adenocarcinoma. The most common in-
dication for PET/CT was staging and the leading
extrathoracic site of uptake on PET-CT was bone.
Seventeen of the 52 patients (32.7 %) had diabetes
and 13/17 (76.5 %) patients were treated with oral an-
tidiabetic drugs. All patients treated with oral antidia-
betic drugs presented diffuse GIT uptake.
GIT findings
The characteristics and sites of incidental FDG uptake in
the PET/CT GIT positive group were described according
to two patterns, focal and diffuse uptake (Table 2). Thirty-
three (63.5 %) of these patients had diffuse uptake and 19
(36.5 %) had focal uptake. Among the 33 patients with dif-
fuse 18F-FDG uptake, uptake was observed in the
oesophagus in 2 cases and in the colon in 31 cases. Among
the 19 patients with focal FDG-uptake, uptake was ob-
served in the oesophagus in 1 case, in the small bowel in 1
case, in the colon in 13 cases (5 in the ascending colon, 4 in
the descending colon, 4 in the sigmoid), in the rectum in 3
cases and in the anal margin in 1 case. The colon was the
most common site of FDG uptake in both groups.
Investigations and diagnosis
Twelve of the 52 patients with incidental GIT findings (dif-
fuse uptake, n = 33; focal uptake, n = 19) were investigated
by colonoscopy (n = 8), gastroscopy (n = 3), and abdomen
CT (n = 1) (Table 3). Investigations were performed in 9
patients with focal GIT uptake (47 %), and 3 patients with
diffuse GIT uptake (9 %).
Of the 9 patients with focal uptake who were investi-
gated, 4 patients were diagnosed with confirmed malig-
nant GIT lesions (colon adenocarcinoma, n = 2; rectal
adenocarcinoma, n = 1; oesophageal metastasis of lung
cancer, n = 1) (Table 3, Fig. 2). One patient had a high
probability of malignant disease (colon carcinoma) based
on a suspicious lesion on PET-CT confirmed by further
abdominal CT scan, but no further investigations were
performed because of the clinical status of this patient
with metastatic lung cancer. Two patients had benign
diseases, including one case of diverticulitis, and one
case of faecal impaction. Colonoscopy was strictly nor-
mal in two patients, with no signs of GIT disease on
follow-up. No additional diagnostic procedure was per-
formed in 10 patients with focal FDG uptake. The rea-
son for not performing additional GIT assessments in
patients with focal FDG uptake was metastatic lung can-
cer with poor functional status despite the high prob-
ability of malignant GIT disease based on PET-CT
findings (n = 4), or a high probability of benign GIT dis-
ease based on benign PET scan findings with no abnor-
mality on abdominal CT scan and subsequent clinical
follow-up (n = 6).
Two of the 3 patients investigated for diffuse FDG up-
take presented signs of erosive oesophagitis and one pa-
tient had no abnormality on colonoscopy, performed in
view of a family history of colon cancer. Of note, none
of the 33 patients with diffuse uptake developed malig-
nant gastrointestinal disease on the basis of subsequent
clinical follow-up.
Overall, the final GIT diagnoses associated with GIT
uptake was malignant disease confirmed (n = 4, 8 %),
high probability of malignant disease (n = 5, 9.5 %), be-
nign disease confirmed (n = 7, 13.5 %) and high probabil-
ity of benign disease (n = 36, 69 %). The GIT
pathological findings in patients with focal uptake modi-
fied the treatment strategy for only one patient, who was
treated by surgery for two independent malignant lesions
in the lung and colon, with no evidence of metastasis.
SUV
Mean SUVmax values were 8.7 ± 5.1 for diffuse FDG up-
take, 6.4 ± 3.8 for focal FDG uptake, 7.05 ± 3 for the ma-
lignant disease confirmed group, 7 ± 3 for the high
probability of malignant disease group, 6.5 ± 6.1 for the
benign disease confirmed group and 8.3 ± 5 for the high
probability of benign disease group. No statistically sig-
nificant differences in terms of mean SUVmax values
were observed between focal and diffuse FDG uptake
groups (p = 0.19) or between the 4 diagnosis groups
(p = 0.69). No statistically significant difference in
terms of mean SUVpeak, SUV50 and SUV41 was
Fig. 1 Flowchart of the retrospective study
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observed between the 4 diagnosis groups among pa-
tients with focal FDG uptake (Table 4). GIT abnor-
malities were identified on CT scan in 7 (37 %) of
the 19 patients with focal FDG-uptake (Table 4).
Discussion
In this series, 23 % of patients (52/230) assessed by
PET/CT imaging for lung cancer exhibited incidental
GIT FDG-uptake. Thirty-three (63.5 %) of these patients
presented diffuse uptake and 19 (36.5 %) presented focal
uptake. Further investigations were performed in 12 of
the 52 patients with incidental GIT findings. A diagnosis
of malignancy was established in 4 of the 12 patients
with focal uptake. No significant differences in mean
SUVmax were observed between the malignant disease
confirmed, high probability of malignant disease, benign
disease confirmed and high probability of benign dis-
ease groups.
Table 2 Characteristics and sites of incidental GIT
18fluorodeoxyglucose uptake on PET/CT images
Diffuse uptake n = 33 Focal uptake n = 19
Location
Oesophagus 2 (6 %) 1 (5.3 %)
Stomach 0 0
Small bowel 0 1 (5.3 %)
Colon 31 (94 %) 13 (68.5 %)
Rectum 0 3 (16 %)
Anal margin 0 1 (5.3 %)
SUVmax 8.7 ± 5.1 6.4 ± 3.8
Data are expressed as mean ± SD or number (%)
SUVmax =maximum standardized uptake value
Table 1 Patient characteristics
Subjects with PET/
CT for lung cancer
PET/CT GIT PET/CT GIT
Positive group Negative group
n = 230 n = 52 n = 178
Age 63 ± 10 66 ± 9 62 ± 10*
Gender
Male 170 (74 %) 39 (75 %) 131 (74 %)
Female 60 (26 %) 13 (25 %) 47 (26 %)
TNM stage
I 29 (12.6 %) 7 (13.5 %) 22 (12 %)
II 29 (12.6 %) 11 (21 %) 18 (10 %)*
III 81 (35.2 %) 12 (23 %) 69 (39 %)*
IV 91 (39.6 %) 22 (42.5 %) 69 (39 %)
Histology
Adenocarcinoma 110 (48 %) 22 (42 %) 88 (49 %)
Squamous cell carcinoma 73 (31.5 %) 17 (33 %) 56 (31 %)
Small cell lung carcinoma 24 (10.5 %) 7 (13.5 %) 17 (10 %)
Others 23 (10 %) 6 (11.5 %) 17 (10 %)
Indications
Staging 196 (85 %) 46 (88.5 %) 150 (84 %)
Restaging 34 (15 %) 6 (11.5 %) 28 (16 %)
Extrathoracic Hypermetabolic state 125 (54 %) 52 (100 %) 73 (41 %)
Adrenal glands 18 (7.8 %) 8 (15 %) 10 (6 %)*
Bone 45 (20 %) 11 (21 %) 34 (19 %)
Brain 5 (2 %) 2 (4 %) 3 (2 %)
Head and neck 24 (10.5 %) 4 (8 %) 22 (11 %)
Muscle 10 (4.3 %) 6 (11.5 %) 4 (2 %)
Thyroid 3 (1.3 %) 0 3 (2 %)
Others 39 (17 %) 5 (10 %) 34 (19 %)
Data are expressed as number with percentages in parentheses (%) or mean ± SD
* p value < 0.05
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With the increasing use of PET/CT imaging, the man-
agement dilemma posed by patients with incidental
PET/CT findings unrelated to the primary malignancy is
likely to become an increasingly common situation. In
our study, 23 % of cases presented incidental GIT FDG
uptake. This prevalence is higher than that reported in
other studies performed in all types of cancer with GIT
FDG uptake rates ranging from 1.3 to 3 % [15, 20].
The gastrointestinal tract is a common site of physio-
logical and incidental FDG uptake [12-23]. Focal tracer
uptake is commonly seen at the gastro-oesophageal junc-
tion with moderate uptake in the stomach, low-intensity
uptake in the small bowel, and diffuse or focal uptake in
the colon. Higher uptake has been described in the cae-
cum and ascending colon, presumably due to the higher
concentration of lymphocytes [16, 26]. Other mechanisms
for this physiological activity have been attributed to up-
take by muscular peristaltic activity (mainly in the bowel),
swallowed secretions or excretion and intraluminal con-
centration of FDG [27, 28]. Increased FDG uptake can
also be related to inflammation such as enterocolitis,
pseudomembranous colitis, inflammatory bowel disease,
and ulcerative colitis [20, 29–31], or iatrogenic causes
such as oral antidiabetic drugs. In this study, all patients
taking oral antidiabetic drugs presented diffuse GIT up-
take and no additional investigation was performed. It
should be noted that all cases of positive GIT uptake were
reviewed by a nuclear medicine physician, allowing the
GIT FDG uptake results to be considered as robust. In
previous studies, two patterns of GIT FDG uptake have
been described, diffuse and focal uptake. In our study, 33/
52 patients presented diffuse uptake. Three patients with
diffuse uptake, including 2 patients with oesophageal FDG
uptake, were further investigated. As described in the lit-
erature, no case of malignancy was found in patients with
diffuse uptake in our study [17]. Focal GIT uptake must
be interpreted cautiously and further investigations are
highly recommended in these patients. In our study, 9/19
patients were investigated following the detection of focal
FDG uptake. Note that the prevalence of focal FDG up-
take in our study was higher than that reported in other
studies including all types of cancer [24]. Previous studies
have shown that the majority of foci of incidental FDG up-
take in the GIT, especially in the colon and rectum, were
confirmed to be due to significant pathology [13, 15, 18,
20], while only a small proportion of sites in the rest of
the GIT was attributed to malignancy. A significant GIT
disease (cancer, diverticulitis, erosive oesophagitis, ulcera-
tive colitis) was diagnosed in 58 % of patients undergoing
further GIT investigations in our study. Fifty-five percent
of patients with focal FDG uptake investigated in our
study presented malignant disease or a high probability of
malignant disease. Similar results have been reported in
two recent studies with colon cancer diagnosed in 33 %
and 35 % of patients with incidental GIT FDG PET/CT
uptake associated with pulmonary nodules [24, 25]. These
findings are consistent with most published studies,
thereby emphasizing the need for further GIT investiga-
tions to confirm focal FDG uptake, especially in the colon.
Table 3 Investigations and diagnosis of incidental gastrointestinal tract findings
Focal uptake (n = 19) Diffuse uptake (n = 33) Total (n = 52)
Investigations 9 3 12 (23 %)
Colonoscopy 7 1 8 (67 %)
Gastroscopy 1 2 3 (25 %)
CT abdomen 1 0 1 (8 %)
Diagnosis
Malignant disease confirmed 4 0 4 (8 %)
High probability of malignant disease 5 0 5 (9.5 %)
Benign disease confirmed 4 3 7 (13.5 %)
High probability of benign disease 6 30 36 (69 %)
Data are expressed as number (%)
Fig. 2 Coronal and axial positron emission tomography scan
showing unexpected focal rectal uptake. The final diagnosis was
rectal adenocarcinoma
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Chopra et al. [38], in a retrospective analysis of PET/CT
scan reports of patients with lung cancer, showed that the
large bowel was the commonest site for incidental findings
and detected malignant or premalignant abnormalities in
76 % of patients undergoing colonoscopy.
Gastrointestinal cancer and lung cancer present a number
of risk factors in common, such as age and smoking. Age re-
mains the most significant risk factor for colorectal cancer
and most patients with lung cancer are also elderly. Smok-
ing is a known risk factor for stomach and oesophagus can-
cer and Giovannucci et al. recently speculated that smoking
may be the potential cause of up to one in five colorectal
cancers [32].
Colorectal cancer was detected incidentally in 3 of a
series of 230 (1.3 %) patients, which is higher than the rate
observed in various FDG PET/CT cancer screening stud-
ies, such as that reported by Chen et al. with a colorectal
cancer incidence of 0.19 % (6/3210), Terauchi et al. with
an incidence of 0.96 % (28/2911), and Purandare et al.
with an incidence of 0.055 % (5/9000) [33–35] probably
related to potential common risk factors between colon
cancer and lung cancer in our series.
No significant difference in SUVmax was observed the
two groups with focal or diffuse incidental GIT uptake,
and no significant difference in SUVmax, SUVpeak,
SUV50 and SUV41 was observed between the four diag-
nosis groups, confirming previously published data [13,
14, 18–20, 23, 35, 36]. In our study, the mean SUVmax
of diffuse FDG uptake was slightly higher than the mean
SUVmax of focal FDG uptake, although diffuse FDG up-
take was generally associated with a benign diagnosis.
The SUVmax value was not significantly different be-
tween malignant and benign lesions and no cut-off value
was identified for SUVmax in our study [23–37].
Our study presents a number of limitations. First, the
study is limited by its retrospective design. Second, a rela-
tively small number of patients was included in our study,
and a small number of patients were considered for further
GIT investigations, mainly due to the presence of meta-
static disease. Of note, our population was selected on the
basis of a final diagnosis of lung cancer, excluding patients
with benign or secondary pulmonary nodules [24]. Despite
these limitations, this study demonstrates a high incidence
of GIT PET/CT uptake associated with lung cancer, and
found that a focal pattern of FDG uptake was frequently as-
sociated with malignant disease or a high probability of ma-
lignant disease in the GIT.
Conclusion
In conclusion, positive GIT findings on FDG-PET/CT im-
aging during staging or restaging of lung cancer may consti-
tute a clinically significant finding, especially when uptake is
focal and localized in the colon or rectum. The high inci-
dence of GIT cancer associated with lung cancer in our
study indicates the need for careful analysis of PET/CT im-
aging and further GIT investigations in patients with focal
GIT FDG uptake.
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